{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:15:56Z","timestamp":1768691756687,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jpba.2016.07.033","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T22:51:32Z","timestamp":1469832692000},"page":"542-550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components"],"prefix":"10.1016","volume":"129","author":[{"given":"Pierre A.J.","family":"Mourier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9deric","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sizun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Viskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2016.07.033_bib0005","series-title":"Heparin-Binding Proteins","author":"Conrad","year":"1998"},{"key":"10.1016\/j.jpba.2016.07.033_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0008-6215(00)81050-2","article-title":"Further characterization of the antithrombin-binding sequence in heparin","volume":"100","author":"Thunberg","year":"1982","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jpba.2016.07.033_bib0015","series-title":"Hemostasis and Thrombosis: Basic Principles and Clinical Practice","first-page":"3","article-title":"Overview of hemostasis","author":"Colman","year":"2006"},{"key":"10.1016\/j.jpba.2016.07.033_bib0020","series-title":"Chemistry and Biology of Heparin and Heparan Sulfate","first-page":"1","article-title":"Structure and active domains of heparin","author":"Casu","year":"2005"},{"key":"10.1016\/j.jpba.2016.07.033_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0065-2318(01)57017-1","article-title":"Structure and biological interactions of heparin and heparan sulfate","volume":"57","author":"Casu","year":"2001","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ancr.2014.12.001","article-title":"Quantitative compositional analysis of heparin using exhaustive heparinase digestion and strong anion exchange chromotography","volume":"3","author":"Mourier","year":"2015","journal-title":"Anal. Chem. Res."},{"key":"10.1016\/j.jpba.2016.07.033_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.carres.2006.12.010","article-title":"Characterization of di- and monosulfated unsaturated heparin disaccharides with terminal N-sulfated 1 6-anhydro-\u03b2-D-glucosamine or N-sulfated 1,6-anhydro-\u03b2-D-mannosamine residues","volume":"342","author":"Mascellani","year":"2007","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jpba.2016.07.033_bib0040","unstructured":"P. Mourier, C. Viskov, Method for determining specific groups constituting heparins or low molecular weight heparins, U.S. Patent 2005\/0119477 A1, Chem. Abstr. 142 (2005) 89363."},{"key":"10.1016\/j.jpba.2016.07.033_bib0045","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2009.03447.x","article-title":"Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026","volume":"7","author":"Viskov","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jpba.2016.07.033_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.drudis.2012.11.002","article-title":"Low molecular weight heparins copies: are they considered to be generics or biosimilars?","volume":"18","author":"Minghetti","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpba.2016.07.033_bib0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jpba.2015.07.038","article-title":"Analytical and statistical comparability of generic enoxaparins from the US market with the originator product","volume":"115","author":"Mourier","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2016.07.033_bib0060","doi-asserted-by":"crossref","first-page":"8275","DOI":"10.1021\/acs.analchem.5b01366","article-title":"Differentiation of generic enoxaparins marketed in the United States by employing NMR and multivariate analysis","volume":"87","author":"Guerrini","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ab.2014.02.005","article-title":"Liquid chromatography-diode array detection-mass spectrometry for compositional analysis of low molecular weight heparins","volume":"451","author":"Wang","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0070","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1021\/ac303185w","article-title":"Structural analysis of low molecular weight heparin by ultraperformance size exclusion chromatography\/time of flight mass spectrometry and capillary zone electrophoresis","volume":"85","author":"Zhang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0075","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.1021\/ac302232c","article-title":"Top-down approach for the direct characterization of low molecular weight heparins using LC-FT\u2013MS","volume":"84","author":"Li","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0080","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1021\/ac501301v","article-title":"Bottom-up low molecular weight heparin analysis using liquid chromatography\u2013fourier transform mass spectrometry for extensive characterization","volume":"86","author":"Li","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1160\/TH14-05-0411","article-title":"Structural and functional analyses of biosimilar enoxaparins available in Brazil","volume":"113","author":"Oliveira","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jpba.2016.07.033_bib0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.carres.2015.01.016","article-title":"Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography\u2013electrospray mass spectrometry","volume":"407","author":"Xu","year":"2015","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jpba.2016.07.033_bib0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0014-5793(76)80592-3","article-title":"Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin","volume":"66","author":"H\u00f6\u00f6k","year":"1976","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jpba.2016.07.033_bib0100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ab.2004.06.020","article-title":"Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases","volume":"332","author":"Mourier","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ab.2014.02.013","article-title":"Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin","volume":"453","author":"Mourier","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/glycob\/5.1.83","article-title":"Preparation and structural characterization of large heparin-derived oligosaccharides","volume":"5","author":"Pervin","year":"1995","journal-title":"Glycobiology"},{"key":"10.1016\/j.jpba.2016.07.033_bib0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0008-6215(89)84127-8","article-title":"Study of structurally defined oligosaccharide substrates of heparin and heparin monosulfate lyases","volume":"190","author":"Rice","year":"1989","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.jpba.2016.07.033_bib0120","unstructured":"U.S. Pharmacopeia\u2013National Formulary (USP\u2013NF), Test for 1,6-anhydroderivative for enoxaparin sodium, U.S. Pharmacopeial Convention, 2009. http:\/\/www.usp.org\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/genChapter207.pdf (accessed 20.03.16)."},{"key":"10.1016\/j.jpba.2016.07.033_bib0125","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cber.19941271215","article-title":"Novel, very strong, uncharged auxiliary bases; design and synthesis of monomeric and polymer-bound Triaminoiminophosphorane bases of broadly varied steric demand","volume":"127","author":"Schwesinger","year":"1994","journal-title":"Chem. Ber."},{"key":"10.1016\/j.jpba.2016.07.033_bib0130","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/jlac.199619960705","article-title":"Extremely strong, uncharged auxiliary bases; monomeric and polymer-supported polyaminophosphazenes (P2\u2013P5)","author":"Schwesinger","year":"1996","journal-title":"Liebigs Ann."},{"key":"10.1016\/j.jpba.2016.07.033_bib0135","doi-asserted-by":"crossref","first-page":"26662","DOI":"10.1074\/jbc.M801102200","article-title":"Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue","volume":"283","author":"Guerrini","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2016.07.033_bib0140","unstructured":"V. Biberovic, L. Grondard, P. Mourier, C. Viskov, Mixture of sulfated oligosaccharides, U.S. Patent (2011) 8003623 B2."},{"key":"10.1016\/j.jpba.2016.07.033_bib0145","doi-asserted-by":"crossref","first-page":"25895","DOI":"10.1074\/jbc.M113.485268","article-title":"Heparin dodecasaccharide containing two antithrombin-binding pentasaccharides: structural features and biological properties","volume":"288","author":"Viskov","year":"2013","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516304058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516304058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:06:50Z","timestamp":1718726810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516304058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":29,"alternative-id":["S0731708516304058"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2016.07.033","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2016.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}